RP-L201
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukocyte Adhesion Defect - Type I
Conditions
Leukocyte Adhesion Defect - Type I
Trial Timeline
Aug 30, 2019 → Sep 12, 2023
NCT ID
NCT03812263About RP-L201
RP-L201 is a phase 1/2 stage product being developed by Rocket Pharmaceuticals for Leukocyte Adhesion Defect - Type I. The current trial status is completed. This product is registered under clinical trial identifier NCT03812263. Target conditions include Leukocyte Adhesion Defect - Type I.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03812263 | Phase 1/2 | Completed |
| NCT03825783 | Phase 1 | Withdrawn |
Competing Products
1 competing product in Leukocyte Adhesion Defect - Type I
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RP-L201 | Rocket Pharmaceuticals | Phase 1 | 25 |